Nuvation Bio Inc. Price & Performance (NUVB-WT)

Nuvation Bio has launched an Expanded Access Program in the U.S. for taletrectinib, targeting patients with advanced ROS1-positive non-small cell lung cancer. This move comes ahead of the FDA's June 2025 decision on the drug. Taletrectinib has already received approval in China, showcasing its growing global footprint.12

Jones Trading has initiated coverage on Nuvation Bio with a "Buy" rating and a $10 price target. The stock, currently trading at $2.29, has gained 22% in the past week. Analysts cite the company's transition to a commercial stage and upcoming FDA decisions as key factors driving optimism.23

Nuvation Bio has finalized a $250 million financing deal with Sagard Healthcare Partners to support the U.S. launch of taletrectinib. The funding, a mix of royalty and debt financing, is contingent on FDA approval by September 2025. This ensures resources for commercialization without diluting shareholder equity.14